Go Deep
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -35,651 | -45.0 | 105.86 | 2.70 | 16,281.74 |
| Oct 2026 | -34,867 | -44.4 | 104.38 | 2.70 | 15,892.93 |
| Oct 2026 | -30,286 | -41.8 | 98.29 | 2.70 | 14,886.93 |
| Oct 2026 | -32,256 | -43.4 | 102.00 | 2.70 | 15,402.38 |
| Oct 2026 | -32,111 | -41.7 | 101.73 | 2.70 | 15,363.75 |
| Oct 2026 | -30,560 | -42.0 | 98.81 | 2.70 | 14,883.51 |
| Oct 2026 | -30,116 | -41.7 | 97.97 | 2.70 | 14,773.34 |
| Oct 2026 | -31,375 | -42.7 | 100.34 | 2.70 | 15,130.80 |
| Oct 2026 | -30,283 | -41.8 | 98.29 | 2.70 | 14,784.14 |
| Oct 2026 | -30,203 | -41.7 | 98.14 | 2.70 | 14,731.58 |
| Oct 2026 | -26,520 | -38.8 | 91.20 | 2.70 | 13,747.21 |
Axsome Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 218,375,000.0 | 191,203,000.0 | 195,999,000.0 | 170,992,000.0 |
| Net Profit | -51,314,000.0 | -64,542,000.0 | -28,559,000.0 | -47,229,000.0 |
| EPS | -1.0 | -1.3 | -0.6 | -0.9 |
Axsome Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 638,496,000.0 | 385,693,000.0 | 270,600,000.0 | 50,037,000.0 | — |
| Net Profit | -183,174,000.0 | -287,216,000.0 | -239,238,000.0 | -187,134,000.0 | — |
| EPS | -3.7 | -6.0 | -5.3 | -4.6 | — |
Axsome Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 689,805,000.0 | 568,498,000.0 | 588,236,000.0 | 331,476,000.0 | — |
| Total Liabilities | 601,510,000.0 | 511,483,000.0 | 397,259,000.0 | 221,920,000.0 | — |
| Total Equity | 88,295,000.0 | 57,015,000.0 | 190,977,000.0 | 109,556,000.0 | — |
Owes vs Owns
Axsome Therapeutics, Inc. owed $0.89 for every $1 it owned in Jun 2026, up from $0.67 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.89× | 0.87× | 0.90× | 0.68× | 0.67× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Axsome Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 46.8%Receivables 32.5%Inventory 4.1%Fixed assets (tangible) 3.1%Intangible assets 7.6%Other assets 5.9%
How it's funded — Dec 2025
Short-term debt 10.1%Long-term debt 17.1%Payables 9.5%Other liabilities 50.5%Shareholders' equity 12.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 322.9 | 315.4 | 386.2 | 200.8 |
| Receivables | 224.5 | 142.0 | 94.8 | 37.7 |
| Inventory | 27.9 | 15.7 | 15.1 | 4.3 |
| Fixed assets (tangible) | 21.4 | 6.0 | 7.6 | 1.1 |
| Intangible assets | 52.6 | 58.9 | 65.3 | 70.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 40.5 | 30.5 | 19.1 | 17.5 |
| Liabilities & equity | ||||
| Short-term debt | 70.0 | 3.3 | 1.3 | 0.4 |
| Long-term debt | 117.7 | 180.7 | 178.1 | 94.3 |
| Payables | 65.5 | 72.0 | 40.7 | 38.6 |
| Other liabilities | 348.2 | 255.5 | 177.2 | 88.6 |
| Shareholders' equity | 88.3 | 57.0 | 191.0 | 109.6 |
| Net tangible assets | 35.7 | -1.9 | 125.6 | 39.6 |
Axsome Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -93,405,000.0 | -128,410,000.0 | -145,080,000.0 | -116,511,000.0 | — |
| Investing Activities | -480,000.0 | -270,000.0 | -582,000.0 | -53,702,000.0 | — |
| Financing Activities | 101,465,000.0 | 57,840,000.0 | 331,013,000.0 | 284,582,000.0 | — |